A 56-year-old man presented with a 5-month history of upper abdominal pain and vomiting. Physical examination revealed a distended abdomen and high-pitched bowel sounds. Laboratory data were within reference ranges. He underwent abdominal ultrasound and computed tomography, both of which showed significantly thickened jejunal loops. Esophagogastroduodenoscopy and ileocolonoscopy were unremarkable and tissue specimens from the stomach, duodenum, rectum, colon, and ileum showed no abnormalities on histological examination.

The patient underwent double-balloon enteroscopy, where a localized segment of ulcerated mucosa, 4 cm × 5 cm in size, was seen in the proximal jejunum (Video 1). The remaining jejunum, a segment 45 cm in length, appeared edematous. Histological examination after hematoxylin and eosin staining (Figure 1a, b), Congo-red staining in polarized light (Figure 1b, insert), anti-amyloid P-component antibody studies (Figure 1c), and anti-lambda light chain antibody studies (Figure 1d) revealed submucosal amyloid deposits. No amyloid deposits were found in the stomach, duodenum, ileum, colon, or rectum. Systemic amyloidosis was also excluded by bone marrow biopsy, abdominal fat-pad aspiration biopsy, and additional biopsies of the rectal mucosa. Furthermore, serum and immunoelectrophoresis and radiological investigations did not show any abnormalities. A hereditary form of amyloidosis was searched for but subsequently excluded by extensive genetic analyses of the ApoA-I gene.

We have presented an unusual case of intestinal pseudo-obstruction caused by localized primary intestinal AL-type amyloidosis. Amyloid proteins are classified into several types: amyloid light chain protein (AL) in primary amyloidosis, amyloid A protein (AA) in secondary amyloidosis, and transthyrein in familial amyloidosis [1]. Although gastrointestinal involvement is not uncommon in systemic amyloidosis, primary intestinal amyloidosis is extremely rare [1–3]. Systemic chemotherapy with melphalan has been used to treat patients with localized amyloidosis, but this therapy has been associated with severe and life-threatening complications such as multiple bowel perforations in patients without monoclonal gammopathy [3]. Furthermore, clinical studies have demonstrated that patients with localized AL amyloidosis can remain stable over several years [1, 4]. We therefore decided to treat our patient conserva-
tively, and he has remained clinically stable, without any evidence of progressive disease.

References


Corresponding author

K. Mönkemüller, M.D.
Universitätsklinikum Magdeburg
Otto-von-Guericke University
Leipziger Straße 44
39120 Magdeburg
Germany
Fax: +49-391-6713105
Email: Klaus.Moenkemueller@medizin.uni-magdeburg.de